3d
MedPage Today on MSNFor Your Patients: What Is Multiple Myeloma?Although the cause of multiple myeloma is not known, research shows that genetic changes in the DNA of a single plasma cell ...
Regeneron Pharmaceuticals has received a positive opinion from the European Medicines Agency’s human medicines committee for ...
An elderly patient who was initially suspected of having antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) was instead diagnosed with multiple myeloma, according to a case report ...
Follow along on our guide to Multiple Myeloma, a cancer of the bone marrow's infection-fighting plasma cells. As cancerous ...
Multiple myeloma (MM) is a blood cancer that affects plasma cells in bone marrow. It’s a particularly insidious form of ...
17h
Pharmaceutical Technology on MSNIndonesia approves Antengene’s Xpovio NDA for multiple indicationsAntengene’s new drug application (NDA) for Xpovio (selinexor) has gained approval from the Indonesia National Agency of Drug ...
Alfred L. Garfall, MD, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.
After being diagnosed with multiple myeloma, Valarie Traynham turned her journey into a mission—raising awareness, educating ...
2d
GlobalData on MSNHealthTree introduces AI-powered tool to match myeloma patients with trialsThe HealthTree Foundation has announced the launch of the new artificial intelligence (AI)-powered personalised Clinical ...
3d
GlobalData on MSNSkylineDx study highlights value in combined myeloma diagnostic approachSkylineDx’s SKY92 test with fluorescence in situ hybridisation testing led to more accurate identification of high-risk ...
Patients with RA who have used b/tsDMARDs demonstrated similar risks for multiple myeloma when compared with those taking only csDMARDs.
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Multiple myeloma is a rare blood cancer of the plasma cells in bone marrow -- the soft, spongy interior of bone where ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results